Nanosonics Limited

ASX NAN.AX

Nanosonics Limited Return on Equity (ROE) for the year ending June 30, 2024: 7.12%

Nanosonics Limited Return on Equity (ROE) is 7.12% for the year ending June 30, 2024, a -41.33% change year over year. Return on equity measures profit against shareholder equity; higher ROE indicates superior profitability and value creation.

Nanosonics Limited Return on Equity (ROE) for the year ending June 30, 2023 was 12.13%, a 349.73% change year over year.
Nanosonics Limited Return on Equity (ROE) for the year ending June 30, 2022 was 2.70%, a -57.36% change year over year.
Nanosonics Limited Return on Equity (ROE) for the year ending June 30, 2021 was 6.33%, a -22.46% change year over year.
Nanosonics Limited Return on Equity (ROE) for the year ending June 30, 2020 was 8.16%, a -33.96% change year over year.

Key data

Date	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio

ASX: NAN.AX

Nanosonics Limited

CEO	Mr. Michael C. Kavanagh BSc, M.B.A.
IPO Date	May 17, 2007
Location	Australia
Headquarters	Building A
Employees	466
Sector	Health Care
Industries Biotechnology Medical Instruments

Description

Nanosonics Limited, together with its subsidiaries, operates as an infection prevention company in Australia and internationally. The company engages in the manufacturing and distribution of the trophon ultrasound probe disinfector, and its associated consumables and accessories; and research, development, and commercialization of infection control and decontamination products and related technologies. It provides trophon2, an ultrasound probe high level disinfection device; trophon EPR, a low temperature high level disinfection solution for intra-cavity ultrasound probes; and Nanosonics AuditPro, an infection control workflow compliance management solution. Nanosonics Limited was incorporated in 2000 and is headquartered in Macquarie Park, Australia.

Key trends

Past 5 years